Table 3.
HR-QoL from CDK4/6 inhibitors real-world experiences in BC patients
| Author (year) | Intervention | Setting | N | Evaluation tools | Evaluation timepoints | HR-QoL outcomes | Ref |
|---|---|---|---|---|---|---|---|
| Loi (2021) | Palbociclib + letrozole | Advanced | 252 | EQ-5D | Baseline, every cycle, EoT | No significant changes in GHS from baseline | 59 |
| Rahman (2022) | Palbociclib + letrozole | Advanced | 88 | FACIT-F | Screening, baseline, third week for 6 cycles | 24% New-onset fatigue during treatment; 15% severe fatigue | 63 |
| Richardson (2021) | Palbociclib + ET | Advanced | 139 | SF-12, CES-D-10, targeted questions |
Baseline, different evaluations on daily, weekly and monthly base for 6 months | No significant changes in GHS from baseline; low depression incidence | 62 |
| Rocque (2020) | Palbociclib + ET | Advanced | 522 | EORTC QLQ-C30 | Baseline, q3 months, EoT | No significant changes in GHS status from baseline; trend towards pain improvement | 60 |
| Rocque (2021)a | Palbociclib + ET | Advanced | 233 | EORTC QLQ-C30 | Baseline, q3 months, EoT | No significant changes in GHS from baseline | 61 |
| Stearns (2018) | Palbociclib + letrozole | Advanced | 334 | EQ-5D | Baseline, every cycle, EoT | No significant changes in GHS from baseline | 58 |
| Oswald (2021) | CDK4/6 inhibitor + ET | Advanced | 20 | FACT-B, FACT-G, FACIT-F, BCPT, NEQ |
1-Time evaluation | HR-QoL scores 104.8 (SD 18.4) with the FACT-B and 80.3 (SD 12.5) with the FACT-G; mean fatigue score 33.8 (SD 12.1); patients slightly to moderately bothered at the BCPT symptoms scale; 2.8 average unmet needs at the NEQ |
64 |
BC, breast cancer; BCPT, Breast Cancer Prevention Trial; BPI-sf, Brief Pain Inventory-short form; CDK4/6, cyclin-dependent kinase 4/6; CES-D-10, Center for Epidemiological Studies Depression Scale; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EoT, end of treatment; EQ-5D, EuroQoL five dimensional; ET, endocrine treatment; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FACT-B, Functional Assessment of Cancer Therapy-Breast; FACT-G, Functional Assessment of Cancer Therapy-General; HR-QoL, health-related quality of life; GHS, global health status; NEQ, Needs Evaluation Questionnaire; SD, standard deviation; SF-12, Short Form-12.
Black, indigenous and people of color subpopulation of the POLARIS study (interim analysis of total population reported by Rocque et al.60 in 2020).